Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Lung Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of rebeccamycin analogue is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two rebeccamycin analogue regimens in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Key facts
- Study ID
- NCT00006017
- Run by
- Case Comprehensive Cancer Center
- People needed
- 42
- Starts
- 2000-05-01
- Expected to finish
- 2005-01-01
- Last updated by the study team
- 2010-06-10
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Henry Ford Hospital — Detroit, Michigan, United States
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.